Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02701985 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
A Phase 2 study of Sjogren's Syndrome, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 20
- Study locations
NCT02701985 is a Phase 2 study of Sjogren's Syndrome that has completed, run by Hoffmann-La Roche. The registered enrollment target is 75 participants, below the 285-participant average among 20 other Sjogren's Syndrome trials with a reported enrollment target (74% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT02701985, a Phase 2 study of Sjogren's Syndrome, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, double-blind, placebo-controlled, two-treatment arm, parallel-group study designed to evaluate the effects of RO5459072 treatment on disease activity and symptoms of Sjogren's syndrome in adult participants with moderate to severe primary Sjogren's syndrome. The total duration of the study for each participant will be approximately 18 weeks (including screening).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RO5459072
Study Locations (20)
Other
- Hopital Avicenne, Paris - Bobigny
- C.H.U. Ambroise Pare (AP-HP) - Boulogne-Billancourt
- Hopital La Cavale Blanche; Rhumatologie - Brest
- Hopital Lapeyronie; Immunologie Rhumatologie - Montpellier
- Charité Research Organisation GmbH - Berlin
- Szpital Uniwersytecki; nr 2 im. Dr J. Biziela; Klinika Reumatologii i Ukladowych Chorob - Bydgoszcz
- MedPolonia - Poznan
- Niepubliczny Opieki Zdrowotnej; Reumatika - Ctr Reum. - Warsaw
Pennsylvania
- Altoona Center For Clinical Research - Duncansville
- University of Pittsburgh Medical Center - Pittsburgh
- Clinical Research Center of Reading - Wyomissing
California
- Wallace Rheumatic Study Center - Beverly Hills
Colorado
- Denver Arthritis Clinic - Denver
Louisiana
- Ochsner Clinic Foundation - Baton Rouge
Maryland
- John Hopkins Bayview Medical Center - Baltimore
Michigan
- University Of Michigan - Ann Arbor
New York
- Winthrop University Hospital - Mineola
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2016-07-05 |
| Est. Completion | 2017-07-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02701985
The ClinicalTrials.gov registry entry for NCT02701985 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 285-participant average among 20 other Sjogren's Syndrome trials with a reported enrollment target (74% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sjogren's Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02701985 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, Pennsylvania, California.
Frequently Asked Questions
What is clinical trial NCT02701985 about?
NCT02701985 is a clinical study titled "A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome". This is a randomized, double-blind, placebo-controlled, two-treatment arm, parallel-group study designed to evaluate the effects of RO5459072 treatment on disease activity and symptoms of Sjogren's syndrome in adult participants with moderate to severe primary Sjogren's syndrome. The total duration ...
What is the current status of trial NCT02701985?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2016-07-05. Estimated completion is 2017-07-10.
What conditions does trial NCT02701985 study?
This clinical trial studies the following conditions: Sjogren's Syndrome.
What interventions are being tested in trial NCT02701985?
The interventions under investigation include: Placebo (DRUG), RO5459072 (DRUG).
Who is sponsoring clinical trial NCT02701985?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02701985 being conducted?
This trial has 20 study locations across California, Colorado, Louisiana, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sjogren's Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease
RECRUITING · Phase 2
-
A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome
ACTIVE NOT RECRUITING · Phase 2
-
Etanercept Therapy for Sjogren's Syndrome
COMPLETED · Phase 2
-
Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops
COMPLETED · Phase 2
-
Rheumatology Diet Study
RECRUITING
-
Creating Health Course Study for People With Rheumatological Conditions
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.